Journals / Van Tıp Dergisi / 2017 / Cilt: 24 - Sayı: 2

The Effect of Preoperative Neutrophil-Lymphocyte Ratio on Disease Specific Survival in Testicular Tumor Patients

Testis Tümörlü Hastalarda Ameliyat Öncesi Bakılan Serum Nötrofil-Lenfosit Oranı'nın Hastalığa Özgü Sağ kalım Üzerine Etkisi

Pages
106–109
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, high patient volume and prospective trials are needed to support our results.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The effect of hemogram parameters on survival has been evaluated in many studies for patients who have urogenital tumor.
📊
Key Findings & Data:Material and Methods: The data of 67 patients who were treated for primary testicular tumor at our clinic between January 2000 and December 2010 was evaluated retrospectively.
💡
Conclusion & Impact:However, high patient volume and prospective trials are needed to support our results.
🔬Design:Research Article
📍Scope:2000 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: The effect of hemogram parameters on survival has been evaluated in many studies for patients who have urogenital tumor. In this study, we aimed to evaluate the neutrophil-lymphocyte ratio (NLR) on disease specific survival (DSS) in patients who have testicular tumor. Material and Methods: The data of 67 patients who were treated for primary testicular tumor at our clinic between January 2000 and December 2010 was evaluated retrospectively. Patients' age, histological type of tumor, pathologic stage, serum neutrophil and serum lymphocyte counts and NLR values were recorded. Results: For all patients, mean age, mean serum neutrophil, lymphocyte counts and mean NLR were 33±8, 4800±2100, 1100±520 and 3,69±1.1, respectively. In histopathological examination, pure seminoma, pure non-seminom and mix histologic type were detected in 21(31.4%), 23(34.3%) and 23(34.3%) patients, respectively. Stage 1 disease and stage >=2 disease were revealed in 42(62%) and 25(38%)of the patients. During median 67 months follow-up period, DSS rate was 91%. According to previous studies, we determined NLR cutoff value as 4. Patients were divided into two groups as NLR<=4 and NLR>4. There was no statistically significant difference on DSS between two groups. Conclusion: According to our outcomes, we observed that NLR was not a prognostic factor to predict of DSS. However, high patient volume and prospective trials are needed to support our results.

Özet

Amaç: Birçok çalışmada ürogenital tümöre sahip hastalarda hemogram parametrelerinin sağ kalım üzerine etkisi değerlendirilmiştir. Bu çalışmada testis tümörlü hastalarda nötrofil-lenfosit oranı(NLO)' nın hastalığa özgü sağ kalımı (HÖS) üzerine etkisinin değerlendirilmesi amaçlanmıştır. Gereç ve Yöntem: Kliniğimizde Ocak 2000- Aralık 2010 yılları arasında primer testis tümörü nedeniyle tedavisi planlanan 67 hastanın verileri retrospektif olarak incelendi. Tüm hastaların yaş, tümör histoloji tipi, patolojik evresi, serum nötrofil sayısı, serum lenfosit sayısı ve NLO düzeyleri kaydedildi. Bulgular: Hastaların ortalama yaşı, ortalama kan nötrofil sayısı, ortalama lenfosit sayısı ve ortalama NLO düzeyi sırasıyla 33±8, 4800±2100, 1100±520 3,69±1.1 idi. Histopatolojik incelemede, 21(%31,4) hastada saf seminom, 23(%34,3) hastada saf seminom dışı ve 23(%34,3) hastada mikst histolojik tip olduğu belirlendi. Hastaların 42(%62)'sinde evre 1, 25(%38)'inde evre 2 ve üzeri hastalık izlendi. Ortanca 67 ay takip sonrası tüm hastaların HÖS oranının %91 olduğu belirlendi. Önceki çalışmalara göre NLO sınır değer 4 olarak alındı. Buna göre hastalar NLO 4 olmasına göre 2 gruba ayrılarak karşılaştırıldı. Her iki grup arasında HÖS açısından istatistiksel olarak anlamlı farklılık izlenmedi. Sonuç: Çalışmada elde edilen sonuçlara göre hemogram parametrelerinin HÖS'ü belirlemede prognostik faktör olmadığı izlendi. Ancak sonuçların desteklenmesi için daha fazla hasta sayılı ve prospektif verilere ihtiyaç vardır.

🔖

Cite This Article

HAMİDİ, N., SÜER, E., GÖKCE, M. İ., BEDÜK, M. Y. (2017). The Effect of Preoperative Neutrophil-Lymphocyte Ratio on Disease Specific Survival in Testicular Tumor Patients. Van Tıp Dergisi, Cilt: 24 - Sayı: 2, 106–109. https://ajindex.com/articles/334696

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. La Vecchia C, Bosetti C, Lucchini F, Bertuccio P, Negri E, Boyle P, et al. Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975. Ann Oncol 2010; 21(6): 1323-1360
  2. Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, et al. Guidelines on Testicular Cancer: 2015 Update. Eur Urol 2015; 68(6): 1054-1068
  3. Hoffmann R, Plug I, McKee M, Khoshaba B, Westerling R, Looman C, et al. Innovations in health care and mortality trends from five cancers in seven European countries between 1970 and 2005. Int J Public Health 2014; 59(2): 341-350
  4. Viers BR, Houston Thompson R, Boorjian SA, Lohse CM, Leibovich BC, Tollefson MK. Preoperative neutrophil-lymphocyte ratio predicts death among patients with localized clear cell renal carcinoma undergoing nephrectomy. Urol Oncol 2014; 32(8): 1277-1284. 5. de Martino M, Pantuck AJ, Hofbauer S, Waldert M, Shariat SF, Belldegrun AS, et al. Prognostic impact of preoperative neutrophil-to-lymphocyte ratio in localized nonclear cell renal cell carcinoma. J Urol 2013; 190(6): 1999-2004
  5. Yıldırım ME, Badem H, Karataş ÖF, Çimentepe E, Ünal D. Preoperatif Nötrofil/Lenfosit Oranının Testis Tümörlerinin Evresinin Tespitindeki Prediktif Değeri. Turgut Özal Tıp Mer Derg 2013: 20: 243- 245
  6. Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med 1997; 337(4): 242-253
  7. Kuczyk, MA, Serth J, Bokemeyer C, Jonassen J, Machtens S, Werner M, et al. Alterations of the p53 tumor suppressor gene in carcinoma in situ of the testis. Cancer 1996; 78(9): 1958-1966
  8. Peyret C. Tumeurs du testicule. Synthese et recommandations en onco-urologie. [Testicular tumours. Summary of onco-urological recommendations]. Prog Urol 1993; 2: 60-64
  9. Trigo JM, Tabernero JM, Paz-Ares L, García-Llano JL, Mora J, Lianes P, et al. Tumor markers at the time of recurrence in patients with germ cell tumors. Cancer 2000; 88(1): 162-168
  10. Ishizuka M, Nagata H, Takagi K, Iwasaki Y, Kubota K. Combination of platelet count and neutrophil to lymphocyte ratio is a useful predictor of postoperative survival in patients with colorectal cancer. Br J Cancer 2013; 109(2): 401-407
  11. Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastriccancer. Oncology 2007; 73(3-4): 215-220
  12. Teramukai S, Kitano T, Kishida Y, Kawahara M, Kubota K, Komuta K, et al. Pretreatment neutrophil count as an independent